Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma
Chrystal U. Louis,Chrystal U. Louis,Barbara Savoldo,Barbara Savoldo,Gianpietro Dotti,Gianpietro Dotti,Martin Pule,Eric Yvon,G. Doug Myers,Claudia Rossig,Heidi V. Russell,Oumar Diouf,Oumar Diouf,Enli Liu,Hao Liu,Meng Fen Wu,Adrian P. Gee,Zhuyong Mei,Cliona M. Rooney,Cliona M. Rooney,Helen E. Heslop,Helen E. Heslop,Malcolm K. Brenner,Malcolm K. Brenner +23 more
TLDR
It is shown that GD2-CAR T cells can induce complete tumor responses in patients with active neuroblastoma; these CAR T cells may have extended, low-level persistence in patients, and such persistence was associated with longer survival.About:
This article is published in Blood.The article was published on 2011-12-01 and is currently open access. It has received 957 citations till now. The article focuses on the topics: Cytotoxic T cell & T cell.read more
Citations
More filters
Journal ArticleDOI
Adoptive cell transfer as personalized immunotherapy for human cancer.
TL;DR: The ability to genetically engineer lymphocytes to express conventional T cell receptors or chimeric antigen receptors has further extended the successful application of ACT for cancer treatment.
Journal ArticleDOI
Adoptive immunotherapy for cancer: harnessing the T cell response
TL;DR: Progress in the use of adoptively transferred T cells is discussed, focusing on how they can mediate tumour cell eradication, including more accurate targeting of antigens expressed by tumours and the associated vasculature.
Journal ArticleDOI
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
Adrienne H. Long,Waleed Haso,Jack F. Shern,Kelsey Wanhainen,Meera Murgai,Maria Ingaramo,Jillian P. Smith,Alec J. Walker,M. Eric Kohler,Vikas R Venkateshwara,Rosandra N. Kaplan,George H. Patterson,Terry J. Fry,Rimas J. Orentas,Crystal L. Mackall +14 more
TL;DR: It is shown that tonic CAR CD3-ζ phosphorylation, triggered by antigen-independent clustering of CAR single-chain variable fragments, can induce early exhaustion of CAR T cells that limits antitumor efficacy, and that CD28 costimulation augments, whereas 4-1BB costimulations reduces, exhaustion induced by persistent CAR signaling.
Journal ArticleDOI
The Basic Principles of Chimeric Antigen Receptor Design
TL;DR: This review focuses on the design ofCARs, including the requirements for optimal antigen recognition and different modalities to provide costimulatory support to targeted T cells, which include the use of second- and third generation CARs, costimulation ligands, chimericcostimulatory receptors, and cytokines.
Journal ArticleDOI
Toxicities of chimeric antigen receptor T cells: recognition and management.
TL;DR: The toxicities caused by CAR T cells are described and the published approaches used to manage toxicities are reviewed, with guidelines for treating patients experiencing CRS and other adverse events following CAR T-cell therapy presented.
References
More filters
Journal ArticleDOI
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
TL;DR: In this paper, a class of tests developed for comparing the cumulative incidence of a particular type of failure among different groups is presented. The tests are based on comparing weighted averages of the hazards of the subdistribution for the failure type of interest.
Journal ArticleDOI
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Mark E. Dudley,John R. Wunderlich,Paul F. Robbins,James Chih-Hsin Yang,Patrick Hwu,Douglas J. Schwartzentruber,Suzanne L. Topalian,Richard M. Sherry,Nicholas P. Restifo,Amy M. Hubicki,Michael R. Robinson,Mark Raffeld,Paul H. Duray,Claudia A. Seipp,Linda Rogers-Freezer,Kathleen E. Morton,Sharon Mavroukakis,Donald E. White,Steven A. Rosenberg +18 more
TL;DR: The adoptive transfer of highly selected tumor-reactive T cells directed against overexpressed self-derived differentiation antigens after a nonmyeloablative conditioning regimen resulted in the persistent clonal repopulation of T cells in cancer patients, leading to regression of the patients' metastatic melanoma as well as to the onset of autoimmune melanocyte destruction.
Journal ArticleDOI
Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.
Garrett M. Brodeur,J Pritchard,Frank Berthold,N L Carlsen,Victoria Castel,R P Castelberry,B. De Bernardi,Audrey E. Evans,Favrot M,F Hedborg +9 more
TL;DR: The International Neuroblastoma Staging System (INSS) as mentioned in this paper was proposed to establish an internationally accepted staging system for neuroblastoma, as well as consistent criteria for confirming the diagnosis and determining response to therapy.
Journal ArticleDOI
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
Alice L. Yu,Andrew L. Gilman,M. Fevzi Ozkaynak,Wendy B. London,Susan G. Kreissman,Helen X. Chen,Malcolm A. Smith,Barry D. Anderson,Judith G. Villablanca,Katherine K. Matthay,H. Shimada,Stephan A. Grupp,Robert C. Seeger,C. Patrick Reynolds,Allen Buxton,Ralph A. Reisfeld,Steven D. Gillies,Susan L. Cohn,John M. Maris,Paul M. Sondel +19 more
TL;DR: Immunotherapy with ch14.18, GM-CSF, and interleukin-2 was associated with a significantly improved outcome as compared with standard therapy in patients with high-risk neuroblastoma.
Journal ArticleDOI
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
Martin Pule,Barbara Savoldo,G. Doug Myers,G. Doug Myers,Claudia Rossig,Heidi V. Russell,Heidi V. Russell,Gianpietro Dotti,Gianpietro Dotti,M. Helen Huls,Enli Liu,Adrian P. Gee,Adrian P. Gee,Zhuyong Mei,Eric Yvon,Heidi L. Weiss,Hao Liu,Cliona M. Rooney,Cliona M. Rooney,Helen E. Heslop,Helen E. Heslop,Malcolm K. Brenner,Malcolm K. Brenner +22 more
TL;DR: It is shown in individuals with neuroblastoma that EBV-specific CTLs expressing a chimeric GD2-specific receptor indeed survive longer than T cells activated by the CD3-specific antibody OKT3 and expressing the same chimeric receptor but lacking virus specificity.
Related Papers (5)
Chimeric antigen receptor T cells for sustained remissions in leukemia.
Shannon L. Maude,Noelle Frey,Pamela A. Shaw,Richard Aplenc,David M. Barrett,Nancy Bunin,Anne Chew,Vanessa E. Gonzalez,Zhaohui Zheng,Simon F. Lacey,Yolanda D. Mahnke,J. Joseph Melenhorst,Susan R. Rheingold,Angela Shen,David T. Teachey,Bruce L. Levine,Carl H. June,David L. Porter,Stephan A. Grupp +18 more